logo
Bagel Recall Update As FDA Issues Highest Risk Warning

Bagel Recall Update As FDA Issues Highest Risk Warning

Newsweek02-06-2025
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A number of recalled bagel products made by a Utah-based company have been issued a Class I risk classification by the U.S. Food and Drug Administration (FDA).
New Grains Gluten Free Bakery issued a voluntary recall for a variety of its bagels and breads in May due to the potential undeclared presence of egg—a major food allergen.
Newsweek contacted New Grains Gluten Free Bakery for comment via online contact form on Monday.
Why It Matters
A Class I recall is the highest risk level and is issued when there is a "reasonable probability" that the use of or exposure to a product could "cause serious adverse health consequences or death."
The FDA announcement, posted on the FDA's website, warned that people who have an allergy or severe sensitivity to eggs "run the risk of serious or life-threatening allergic reactions if they consume these products."
Eggs are one of the nine major food allergens as set out in law, which also include milk, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame.
"Food allergic reactions vary in severity from mild symptoms involving hives and lip swelling to severe, life-threatening symptoms, often called anaphylaxis, that may involve fatal respiratory problems and shock," says the FDA.
What To Know
The company, based in Spanish Fork, Utah, issued a recall for four of types of bagels, all gluten free—plain, cinnamon raisin, blueberry, and multigrain. According to the FDA, 100 units of each type of bagel were affected.
The recall was initiated after it was discovered that the products containing allergens, including eggs, were distributed with labels that did not reveal the presence of said allergens.
Additionally, the company has recalled the following bread products due to the undeclared presence of egg:
Artisan White Bread
Artisan Multigrain Bread
Artisan Sourdough Bread
Artisan Cinnamon Raisin Bread
A stock image of bread loaves.
A stock image of bread loaves.The products were distributed between April 4 and 21 under the lot numbers 90-107. The 32oz bread products were packaged in clear, vacuum-sealed plastic bags. A total of 250 units of each product were distributed to retail locations in Utah.
The recall announcement said that no illnesses had been reported.
What Happens Next
The recall is listed as ongoing, according to the FDA. Consumers who have purchased the products are urged not to consume them and to return them to the place of purchase for a full refund.
Separately, products from three different companies have been removed from shelves over the span of four days due to salmonella contamination fears, Newsweek reported on Friday.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Crinetics' treatment of CAH granted FDA orphan designation
Crinetics' treatment of CAH granted FDA orphan designation

Business Insider

time2 hours ago

  • Business Insider

Crinetics' treatment of CAH granted FDA orphan designation

Crinetics (CRNX)' treatment of congenital adrenal hyperplasia, generic name atumelnant, was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation
Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation

Business Insider

time2 hours ago

  • Business Insider

Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation

Keros Therapeutics (KROS)' treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Regenxbio announces FDA review extension for RGX-121 BLA
Regenxbio announces FDA review extension for RGX-121 BLA

Business Insider

time4 hours ago

  • Business Insider

Regenxbio announces FDA review extension for RGX-121 BLA

Regenxbio (RGNX) announced that the U.S. Food and Drug Administration extended its review timeline of the Biologics License Application for clemidsogene lanparvovec for the treatment of Mucopolysaccharidosis II, also known as Hunter syndrome. The Prescription Drug User Fee Act goal date has been extended from November 9, 2025 to February 8, 2026. The extension follows the company's submission of longer-term clinical data for all patients in the pivotal study of RGX-121 in response to an FDA information request. These positive 12-month clinical data are consistent with biomarker and neurodevelopmental data previously submitted on the same patients in the BLA and will be presented during the International Congress of Inborn Errors of Metabolism in September 2025. In August 2025, the FDA completed a pre-license inspection and bioresearch monitoring information inspection for the RGX-121 BLA with no observations. No safety-related concerns have been raised by the FDA during the BLA review. 'Boys with this rare, devastating disease have no treatment options to address neurodevelopmental decline, and the Hunter syndrome community is in urgent need for a therapeutic option with the potential to improve these patients' lives,' said Curran M. Simpson, President and Chief Executive Officer of REGENXBIO. 'We promptly provided the FDA with the information requested and expect the commercial launch plans remain on track.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store